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Abstract
Background: Current surgical and ablative treatment options for prostate cancer (PCa) may result in a high
incidence of (temporary) incontinence, erectile dysfunction and/or bowel damage. These side effects are due to
procedure related effects on adjacent structures including blood vessels, bowel, urethra and/or neurovascular
bundle. Ablation with irreversible electroporation (IRE) has shown to be effective and safe in destroying PCa cells
and also has the potential advantage of sparing surrounding tissue and vital structures, resulting in less impaired
functional outcomes and maintaining men’s quality of life.
Methods/Design: In this randomized controlled trial (RCT) on IRE in localized PCa, 200 patients with organ-
confined, unilateral (T1c-T2b) low- to intermediate-risk PCa (Gleason sum score 6 and 7) on transperineal template-
mapping biopsies (TTMB) will be included. Patients will be randomized into focal or extended ablation of cancer
foci with IRE. Oncological efficacy will be determined by multiparametric Magnetic Resonance Imaging, Contrast-
Enhanced Ultrasound imaging if available, TTMP and Prostate Specific Antigen (PSA) follow-up. Patients will be
evaluated up to 5 years on functional outcomes and quality of life with the use of standardized questionnaires.
Discussion: There is critical need of larger, standardized RCTs evaluating long-term oncological and functional
outcomes before introducing IRE and other focal therapy modalities as an accepted and safe therapeutic option for
PCa. This RCT will provide important short- and long-term data and elucidates the differences between focal or
extended ablation of localized, unilateral low- to intermediate-risk PCa with IRE.
Trial registration: Clinicaltrials.gov database registration number NCT01835977. The Dutch Central Committee on
Research Involving Human Subjects registration number NL50791.018.14.
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Background
Prostate cancer (PCa) is the most common cancer in
men and the second leading cancer-related cause of
death. The incidence of PCa increases steadily, contribu-
tors to this increasing incidence include the ageing
population, increased awareness and implementation of
the Prostate Specific Antigen (PSA) test [1]. Due to the
increasing use of the PSA test and improved diagnostic
technology more patients with early stage, localized PCa
are diagnosed nowadays.
Present therapeutic options by guideline
Currently, there are several treatment options available
for PCa, including surgery, radiotherapy, minimally invasive
ablative techniques and active surveillance. Choice of treat-
ment depends on patients’ choice and risk stratification
(e.g. D’Amico Risk Classifications [2]). Active surveillance is
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an attractive management option for (very) low-risk PCa.
Especially older men, who have the highest incidence of
PCa [1], may be suitable candidates for active surveillance
(AS) since these patients have a limited life-expectancy and
may have co-morbidities. AS can have an impact on quality
of life since patients do not receive treatment for their
cancer and sometimes the window of opportunity to treat
curatively can be missed. For localized disease, a radical
prostatectomy or radiotherapy are the recommended cura-
tive treatments according to the guidelines [3–5]. The most
common side effects associated with radical treatments are:
erectile dysfunction (58–79 %), gastrointestinal toxicity and
proctopathy (13–34 %), incontinence (range 3.2–14 %),
overactive and/or obstructive urinary symptoms and
hematuria (5 %) [6, 7]. It is the result of procedure-related
damage to blood vessels, bowel, urethra and/or neurovas-
cular bundle and may impair the quality of life in PCa pa-
tients following treatment [6].
Focal therapy for localized prostate cancer
The side effect profile of radical treatments opened the
door to focal strategies that limit damage to the important
anatomical urological structures [8, 9]. A variety of abla-
tion techniques have been used, including cryoablation,
high-intensity focused US (HIFU), radiofrequency ablation
(RFA), microwave coagulation, Vascular Targeted Photo-
dynamic Therapy, Interstitial Laser Thermotherapy and
Irreversible Electroporation (IRE) [10]. Focal therapy
gained popularity because of the minimally invasive ap-
proach, short hospital stay, possible improved functional
outcomes, lower complication rate and less impact on the
quality of life [10]. Moreover, focal treatment provides a
more curable treatment option compared to active sur-
veillance and is better tolerated than radical treatments by
older patients with comorbidities. A systematic review on
focal treatment by Valerio et al. has been published, com-
prising a total of 2350 cases across 30 studies with a
follow-up range between 0 and 11.1 year. In PCa initially
treated with focal therapy, the pad-free continence ranged
from 95 to 100 %, retained erectile function ranged from
54 to 100 % and PCa was absent in 50 to 96 % on regular
follow up biopsies [10]. Cheetham and colleagues [11]
published promising long-term survival rates of patients
undergoing primary or salvage cryotherapy for PCa. Re-
sults indicated an 87 % overall 10-year prostate-cancer-
specific survival, despite early cryotherapy technology and
the majority of patients having high-risk PCa.
Irreversible electroporation for prostate cancer
Electroporation is a technique in which high-frequent elec-
tric pulses are generated between two or more electrodes.
The resultant electric current damages the cell membrane,
allowing molecules to pass into the cell passively. The
process of electroporation can either be temporary
(reversible electroporation) or become permanent (IRE)
when a certain electric threshold is reached, causing cell
death due to the inability to maintain homeostasis [11–13].
Initially, the occurrence of IRE during reversible electro-
poration procedures was considered an unwanted side ef-
fect. However, the ability of IRE to induced selective cell
death turned IRE into a tumour ablation modality, leading
to the development of the commercially available Nano-
knife™ (AngioDynamics, Queensbury, New York) [12].
Histopathological outcomes after IRE show a sharp demar-
cation between ablated and non-ablated tissue, whereas
thermal ablation techniques show a transitional zone of
partially damaged tissue due to insufficient temperatures
for definitive ablation [14]. Therefore, IRE tissue ablation
possibly enables more precise procedure planning of the
target area. IRE has shown to effectively ablate tumour
cells in vitro, in animal studies and in phase 1–2 human
trials on IRE (cancer) ablation in several organs (liver, pan-
creas, kidney, lung and prostate) [15–18]. The first phase
1–2 trials on focal therapy of PCa with IRE have shown
promising results, demonstrating a safe and effective focal
treatment modality with low patient morbidity, improved
functional outcomes and good short-term oncological con-
trol [14, 19–22]. No major complications occurred in any
of these trials. All of the patients that were continent be-
fore the IRE procedure remained pad-free continent,
whereas erectile function was preserved in 56 to 95 % of
patients that were potent before [21, 22]. In the Phase I-II
trial on IRE conducted by the Clinical Research Office of
the Endourological Society (CROES) [14], IRE was per-
formed in sixteen patients 30 days prior to their scheduled
radical prostatectomy. The histopathological assessment of
the prostate showed sharply demarcated necrotic and fi-
brotic lesions, without skip lesions [14]. This is in concord-
ance with the other phase 1–2 trials with the exception of
the study of Valerio et al. where 6/34 patients had pos-
sible residual tumour within the ablation zone on multi-
parametric Magnetic Resonance Imaging (mpMRI) [21].
In the aforementioned study, van den Bos et al. per-
formed Transrectal Ultrasound (TRUS), mpMRI and
Contrast-Enhanced Ultrasound (CEUS) imaging follow-
ing IRE to evaluate the ability of the imaging modalities
to accurately visualize IRE ablation effects, ablated area
and possible residual PCa. Both mpMRI and CEUS were
found to be feasible imaging modalities with concord-
ance in volume to the ablated volume on histopathology
with Pearson’s correlation of r = 0.88 and r = 0.80, re-
spectively [23].
At present, no randomized controlled trial (RCT)
(grade 2b) on IRE for treatment-naïve PCa has been
conducted. Moreover, no long-term evidence is available
on functional and oncological outcomes following IRE
treatment in PCa. In this RCT (NCT01835977) 200 pa-
tients with histologically confirmed (on TTMB), organ-
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confined and unilateral low- to intermediate-risk (Gleason
score 6 or 7) PCa will receive ultrasound-guided IRE.
Selected candidates will be randomized to either 1)
focal ablation or 2) extended hemiablation of the
tumour lesions to assess the differences in side effect
profile and efficacy of the treatment and to investigate
if an extended ablation zone is necessary to treat un-
detected satellite lesions adjacent to the index lesion
(Fig. 1) [24]. Patients will be evaluated on urinary
continence, erectile function and quality of life with
the use of standardized questionnaires [25–27]. Onco-
logical efficacy will be determined by TTMP, preceded





– To evaluate the differences in side effects of patients
treated with focal vs extended ablation of PCa with
IRE, measured by CTCAE, IIEF, IPSS and use of pads.
– To evaluate the differences in quality of life of
patients treated with focal vs extended ablation of
PCa with IRE, measured by EPIC, VAS pain score
and length of hospital stay.
Secondary
– To evaluate the oncological efficacy of IRE for focal
vs extended ablation of PCa, measured by TTMB
6 months after IRE and 5 year follow-up with
mpMRI and serial PSA testing.
– To evaluate the utilization of mpMRI in the
oncological follow up after IRE ablation of PCa
and to visualize the extend of the ablation zone,
performed 6 months and 1, 2, 3, 4 and 5 years
following the IRE procedure.
– If available, to evaluate the utilization of CEUS in
the oncological follow up following IRE ablation of
PCa and to visualize the extend of the ablation zone,
performed 6 months and 1, 2, 3, 4 and 5 years
following the IRE procedure.
Expected outcomes
It is expected that focal therapy with IRE in localized
PCa has the potential to improve functional outcomes
and the quality of life of PCa patients compared to
current radical treatment. In line, it is thought that focal
ablation, compared to extended ablation, could better
preserve important anatomical structures and conse-
quently have fewer side effects and a higher quality of life
score. It is shown that the 2D target images produced dur-
ing the preplanning procedure by the Nanoknife™ system
reflect the IRE ablation zone, and could be used as a tem-
plate for pathology [14]. Whole mount pathology analysis
in prostatectomy specimen, obtained with radical prosta-
tectomy 4 weeks following IRE, showed complete haemor-
rhage, necrosis and fibrosis in the ablated zone [14, 19].
Therefore, it is expected to find fibrosis on TTMB in the
according biopsies of the planned ablated zone. Currently,
no long-term oncological outcomes exist on IRE ablation
of localized PCa, so it may be difficult to predict long-
term outcomes. However, short-term oncological out-
comes are promising and the aforementioned study
showed on whole mount pathology no residual PCa in the
ablated zone of all patients [14, 19–22]. It is thought that
mpMRI and CEUS imaging are feasible imaging modal-
ities for the follow-up after focal IRE ablation in localized
PCa since both mpMRI and CEUS were found to accur-
ately visualize on a short-term basis IRE ablation effects
and possible residual PCa [21–23].
Study design
In this prospective RCT, patients with unilateral PCa
(clinical stage T1c-T2b), confirmed on transrectal ultra-
sound(TRUS)-guided biopsies, will be offered extensive
(30-core) TTMB. If the inclusion criteria are met (see
below and Table 1), candidates are randomized into two
groups. One group will undergo a focal ablation of the
prostate (Group A), the other group will receive an ex-
tended hemi ablation (Group B) (Fig. 1). Prior to the
Fig. 1 The Different Ablation Treatments. a Focal Ablation of a PCa lesion in Group A. b Extended Ablation of a PCa lesion in Group B
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procedure, a baseline mpMRI, TRUS and CEUS imaging
(if available) will be obtained and standardized ques-
tionnaires (International Prostate Symptom Score
(IPSS), International Index of Erectile Function (IIEF),
Quality of life-questionnaire (EPIC), Visual Analogue
Scale (VAS)) and number of pads used will be com-
pleted by the patients (Fig. 2). After the focal or ex-
tended IRE ablation, follow-up will be performed
following a strict schedule up to 5 years (Table 2) using
mpMRI, TRUS and CEUS imaging (if available), blood
tests (PSA, Creatinine), adverse event reporting with
Common Terminology Criteria for Adverse Events
(CTCAE) and the use of standardized questionnaires
(IPSS, IIEF, EPIC, VAS). Six months following the IRE
procedure patients will undergo TTMB to determine
ablative effectiveness on pathology and to exclude any
residual or ‘new’ disease. In case of any positive biopsies
on follow-up TTMB, patients will be offered salvage
treatment following the EAU Guidelines on Prostate
Cancer [3].
Population
Two hundred patients (age ≥18 years) diagnosed with
histologically confirmed, unilateral organ-confined PCa
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Histologically confirmed
organ-confined unilateral PCa
on TTMB (clinical stage T1c-T2b)
1. Bleeding disorder (prothrombin
time > 14.5 s., partial
thromboplastin time > 34 s.),
Platelet Count <140/uL,
2. No ability to stop anticoagulant
or antiplatelet therapy
2. Gleason sum score 6 or 7 3. Active (urinary tract) infection
4. History of bladder neck
contracture
5. Major concurrent debilitating
illness or ASA ≥4
6. Cardiac History
3. PSA <15 ng/mL or PSA
>15 ng/mL counselled
with caution
7. Inflammatory bowel disease
8. Major rectal surgery
9. Previous radiation to pelvis
10. Prior or concurrent malignancy
4. Life expectancy of >10 years,
age ≥18 years
11. Biologic or chemotherapy
for PCa
12. Hormonal therapy within last
6 months
13. Any resection or stenting of
the prostate
14. Prostate calcification >5 mm
Fig. 2 Flowchart of the inclusion and randomization process
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(clinical score of T1c-T2b) with positive biopsies number
on transperineal template-guided prostate biopsies and
no evidence of lymph node or distant metastases. Pa-
tients should have an expected life expectancy of >10 years
and serum PSA <15 ng/mL or PSA >15 ng/mL counselled
with caution. Patients known with a cardiac history
including arrhythmias, ICD or pacemaker and patients
with previous pelvic surgery or radiotherapy or PCa
treatment are excluded. For all inclusion and exclusion
criteria, see Table 2.
Study procedures
Transperineal template-mapping biopsies
Extensive transperineal three-dimensional (3D)-template
mapping biopsies are performed using ultrasound
guidance to localize cancer foci by applying the same
transperineal grid used for brachytherapy seed place-
ment. This is considered to be the reference standard
for patient selection in focal therapy for localized PCa
[28]. TRUS biopsy, even with optimized protocols,
has been shown to poorly reflect the tumour grade
and extent of PCa compared with radical prostatectomy
specimens [29, 30]. Needle biopsies will be analysed on
diagnosis/residual/recurrent PCa and tumour grade by a
specialized uro-pathologist.
IRE ablation
The AngioDynamics Inc. HVP-01 Electroporation System
(also registered as the NanoKnife™ IRE System) is the first
commercially available device based on IRE and is used
for tissue ablation that is primarily cellular [13]. It is
approved by the regulatory authorities in Europe (CE
certificate) and meets several international recognized
standards. The NanoKnife™ System and Probes have been
cleared for marketing by the U.S. Food and Drug Adminis-
tration (FDA) via 510(k) Premarket Notifications (K060054,
K080202, K080376, and K080287). The console consists of
two major components; a Low Energy Direct Current
generator and needle electrodes.
Prior to the procedure patients will receive antibiotic
prophylaxis (Ciprofloxacin 500 mg). A maximum of six
IRE electrodes will be placed using a brachytherapy
template-grid into the pre-specified ablation zone using
biplane transrectal ultrasound image guidance to
visualize both sagittal and axial views. The ultrasound
data on prostate dimensions, electrode position and
electrode tip length are transferred into the software
platform and the resultant ablation volume will be deter-
mined and displayed by the Nanoknife™ console (Fig. 3).
When the needles are in place, 90 consecutive pulses
will be delivered of high-voltage (1500 V/cm) with a dir-
ect current between 20 and 50 A. Pulses are delivered
(synchronized with ECG) in groups of 10 at intervals of
100 μs. Between each group, a 3.5 s delay is required to
recharge the capacitor. During the IRE procedure patients
will receive a strong muscle relaxant (Rocuronium) to pre-
vent severe muscle contraction. The total procedure time,
including general anaesthesia, will be approximately 1 h.
After the procedure patient will receive a transurethral
catheter for 24 h. Patients will have an overnight hospital
stay and it is anticipated that the majority of patients will
be discharged the day after the procedure. Procedural and
post procedure Adverse Events (AEs) and Serious AEs will
be reported to the Institutional Review Board (IRB).
Multiparametric magnetic resonance imaging
mpMRI will be performed in supine position on a 1.5 T
AVANTO® MRI scanner (Siemens Healthcare, Erlangen,
Germany) using an integrated endorectal-pelvic phased-
array coil (Medrad, Warrendale, USA). Prior to the
mpMRI, anti-Peristaltic Drugs (Buscopan or Glucagon)
will be given. T2 weighted sequences will be performed
in sagittal, coronal and transverse planes from the aorta
bifurcation to the pubic symphysis, including prostate
Table 2 Overview follow-up scheme
Visits Day −1 Day 0; IRE Day 1 2 weeks 4 weeks 3 months 6 months 1 year 18 months 2 years 30 months 3,4,5 years
Medical History X
Phys. Examination X X X X X X X X X X
Informed Consent X
PSA/Creatinine test X X X X X X X X X X
Questionnaires
(IIEF,IPSS,EPIC,pads)
X X X X X X X X X
Pain-scores (VAS) X X X X X X X X X X X
(mp)MRI and if
available CEUS
X X X X X
TTMB X X
IRE procedure X
AEs reporting X X X X X X X X X X X
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and seminal vesicles. Next, T1 diffusion-weighted with
fat suppression and dynamic contrast-enhanced images
(0.1 mmol of gadopentetate dimeglumine per kg of body
weight, Gadolinium DTPA, Gadovist) are obtained.
mpMRI will be evaluated by a specialized uro-radiologist
(blinded for the randomization) on prostate and ablation
volume, evidence of residual or recurrent PCa according
to the PIRADS (v2) criteria [31], skip lesions within
the target zone, damage to adjacent structures and
lymph node or haematogenous metastasis.
Contrast-enhanced ultrasound
CEUS imaging involves the use of microbubble contrast
agent (SonoVue; Bracco, Milan, Italy) to show blood
flow and tissue perfusion information. The ultrasound
contrast agent consists of a solution of gas-filled shell-
stabilized microbubbles with a diameter of 3–5 μm.
These bubbles stay inside the blood stream and travel
through all blood vessels, including the microvasculature
[32] and are visualized with specialised imaging tech-
niques (Philips iU22; Philips Healthcare, Bothell, USA).
The prostate will be scanned in 4 planes, base, mid-
base, mid-apex and apex. If performed, CEUS imaging
will be analysed on prostate and ablation volume and
evidence of residual or recurrent PCa by the performing
urologist/fellow.
Randomization, sample size and statistical analysis
Randomization
The patients are stratified on baseline total IIEF-score
with cut-off score of 45 points (≤45 vs. >45), Gleason
score (grouped in Gleason sum score 6 vs. sum score 7)
and age with cut-off score of 60 years (≤60 and >60) to
prevent randomly occurring differences in important
prognostic factors across the two randomized groups.
Patients are blinded to the randomized treatment given
(focal or extended ablation) to ensure unbiased assess-
ment. The treating physicians have to be informed about
the actual treatment in order to be able to perform the
ablation. mpMRI findings will be coded and centrally
assessed by a uro-radiologist, blinded for the results of
TTMB and the performed procedure.
Sample size calculation
Since the primary objective of the study is to determine
the side effect profile of IRE, the sample size is powered
on a common event; erectile dysfunction. Ahmed et al.
performed three comparable studies with a concurrent
focal ablation modality (HIFU), and a similar patient
population and the same primary objectives [33–35].
Focal ablation with HIFU led to a decline of 18.2 % on
the IIEF-15 questionnaire (57.5 % to 47.0 % after
12 months). Converting this to the shortened IIEF-5
questionnaire (which is used in this RCT), the mean IIEF
score is 16.61 (SD 4.0) in Group A (focal ablation) and the
mean IIEF score is 15.1 (SD 4.0) in Group B (extended
ablation). A two group Wells-Satterthwaite t-test of equal
means and unequal variances were used to calculate the
sample size. The one-sided (one-tailed) test was used,
because this rejects the null hypothesis for differences in a
single direction. With an α level of 0.05 and power of
80 % (1-β), the sample size required was at least 90 men
per group. The sample size was adjusted to allow for 35 %
of men in the general population (>50 years old) having
Fig. 3 a The Nanoknife console. b Specific ablation zone: with the needles placed 1.5 cm apart, the active electrode length is set at 2 cm and the
resultant ablation volume is calculated at 12.75 cm3
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poor baseline erectile function [36], and therefore aim to
recruit at least 200 men in total.
Statistical analysis
Data will be collected using the Data Management
System of CROES. The validated questionnaires will be
analysed with standard methods. Maximum and mini-
mum values will be set according to the extremes of
questionnaire item scales. Categorical outcomes will
be reported as point estimates with binomial 95 % CIs to
demonstrate level of precision. Wilcoxon signed rank test
(two-tailed) will be used to assess differences between
continuous variables that were not normally distributed
(PSA and questionnaire scores), measured at baseline and
at the subsequent follow-up visit. Changes over time will
be reported with box-and-whisker plots. The group
analyses will be hypothesis-generating and we will run
statistical tests of significance.
Quality and patient safety monitoring
Data will be centrally collected and monitored by the
CROES using their Data Management System. During
the study independent physicians and the IRB, assessing
patient safety and treatment efficacy, will monitor data.
Monitoring criteria are objectively described in the
protocol approved by the IRB, since IRE ablation of soft
tissue is a novel prostate cancer treatment and therefore
holds potential risks and side effects that are unknown
at this time. A clinical risk analysis associated with the
NanoKnife™ device and the procedure is presented in
Table 3. In accordance to section 10, subsection 1, of the
Wet Medisch-Wetenschappelijk Onderzoek met Mensen
(Medical Research Involving Human Subjects Act), the
investigator will inform the subjects and the reviewing
accredited IRB if anything occurs of which the disadvan-
tages of participation may be significantly greater than
was foreseen in the research proposal. The study will be
suspended pending further review by the accredited IRB,
except insofar as suspension would jeopardise the sub-
jects’ health. The local investigator will inform all partici-
pating subjects. Interdepartmental monitoring (IDM) will
take place according to the IDM model in the AMC.
Ethical consideration
This RCT will be conducted in accordance to the stan-
dards of Good Clinical Practice, with the ethical princi-
ples that have their origins in the Declaration of Helsinki
(Fortealeza, Brazil, October 2013) and is approved by
the IRB of the Academic Medical Center, Amsterdam
(2014_303). The protocol is registered with The Dutch
Central Committee on Research Involving Human Sub-
jects (NL50791.018.14) and on the clinicaltrials.gov data-
base (NCT01835977). Potential patients will be informed
about the study by one of the principal investigators or its
representatives, provided with the patients information
form. When patients agree to participate, written in-
formed consent is acquired from all participants.
Availability of data and materials
The study initiator, international coordinating researcher
and biostatistician will have access to all data in the
CROES system, participating centres will only be able to
access and register their own data. All data is available for
audit and all data will be published in an international
peer-reviewed medical journal. After the finalization of
the study, the dataset supporting the conclusions of
this study will not be shared since permission was
not obtained from all participating centres.
Discussion
The first phase I-II trials on focal therapy of PCa with
IRE have shown promising results for IRE as a safe and
effective focal treatment modality with low patient mor-
bidity, improved functional outcome and good short-term
oncological control [14, 21, 22]. However, there is a need
of larger, uniform randomized controlled trials evaluating
long-term oncological outcomes to make IRE an accepted
and safe therapeutic option in PCa. This study will be the
first RCT (Grade 2b) with IRE for treatment-naïve, unilat-
eral low- to intermediate risk PCa, evaluating patients’
functional outcome, quality of life and oncological control
following focal (group A) or extended (group B) ablation.
Two hundred patients will be included and followed
up to 5 years with the use of standardized question-
naires, mpMRI, CEUS imaging if available, TTMB and
serial PSA testing.
In this trial TTMB is used to select patient for focal
therapy in localized PCa, as recommended after an
Table 3 A clinical risk analysis associated with the IRE device
and procedure
Potential risks of IRE
ablation and procedure
Side effect/Adverse event
General Anaesthesia Aspiration, urinary retention, extended
muscle blockage, anaesthetic drug toxicity,
pain, coma, death
Electric current of IRE Cardiac arrhythmias, severe muscle
contraction, electrical shock, death





with consequent side effectsa, bleeding,
infection, pain
Insufficient IRE treatment Residual or recurrent tumour
Insufficient Muscle
Blockade
Muscle strains or damage, electrodes
displaced, trauma
ahaematuria, hematoma, infection, abscess formation, fistula, sepsis, death,
urinary retention, urinary or faecal incontinence, urethra stricture, erectile
dysfunction, necrosis of affected tissue
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international consensus meeting [28]. However, special
computer models of 3D whole mount prostatectomy
specimens were compared in a small series (n = 25) to
their corresponding TTMB cores. Eighteen out of sixty
four lesions were missed (only 1 was clinically significant)
by TTMB and sum Gleason score was upgraded in 12 %
(n = 3) [30]. A concurrent study by Hu et al. showed the
superiority of TTMB above TRUS-guided biopsies in diag-
nosing and staging PCa but TTMB regimen still missed
5 % of ≥0.2 mL and ≥0.5 mL lesions [29]. This highlights
the confounding factor that TTMB has on accurate
patient selection, treatment zone determination and
oncological follow-up. In line, PCa foci may also be
missed on mpMRI. mpMRI data (on a 1.5 T device)
compared to whole mount prostatectomy specimen
showed sensitivity/specificity and positive/negative pre-
dictive values for detection of PCa by mpMRI of 77/91
and 86 %/85 % for foci of >0.2 mL and 90/88 and 77 %/
95 % for foci of >0.5 mL, respectively [37, 38]. However, in
a recent study (n = 50) the combination of mpMRI with
TTMB, used in a RCT, was found to have a high negative
predictive value (91 %) for low-grade, small volume
(>3 mm) PCa, indicating a reliable assessment to prevent
undertreating significant PCa [39]. Since pathological as-
sessment following IRE showed fibrosis without glandular
prostatic ducts and necrotic tissue and no skip lesions
within the ablated zone, we believe IRE effectively ablates
all PCa foci within the target zone. Tumour ablation ex-
periments in animals and humans have shown the poten-
tial to preserve connective tissue structures within the
target zone and limit damage to associated blood vessels,
neural tissue or other vital structures [16–18]. However,
this may not apply to current thorough clinical treatment
protocols [14, 40].
Therefore, in our opinion this RCT will provide import-
ant data on the differences between focal or extended abla-
tion of localized, unilateral low- to intermediate-risk PCa
using IRE, providing essential long-term data on functional
outcome and oncological control.
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